Drug · Adc

Brentuximab Vedotin

CI-DRUG-00000718Explore in graph →CHEMBL1742994 Approved

Regulatory

Approvals (16)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory16 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as ADCETRIS (DIN 02401347) under ATC L01FX05 BRENTUXIMAB VEDOTIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 19, 2013	health-canada-dpd
EU EMA	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):- following ASCT, or- following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Systemic anaplastic large cell lymphomaAdcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.Cutaneous T-cell lymphomaAdcetris is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.	approved	Oct 25, 2012

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 8 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	44	19	19	161	16	CA, EU, US	Aug 19, 2011	2004-09
Hodgkin Lymphoma	Approved	Phase 4	26	10	12	87	4	US	Aug 19, 2011	2006-04
Non-Hodgkin Lymphoma	Approved	Phase 4	15	7	6	54	2	EU, US	Aug 19, 2011	2006-08
Leukemia	Phase2	Phase 2	2	2	0	11	0	—

Curated evidence

Clinical evidence (0)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

Data not yet available

No curated evidence item mentions this therapy yet.

Clinical trials

Trials with this intervention (167)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 101–150 of 167 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	terminated	Phase 1 / Phase 2	20	Northwestern UniversityOTHER	1	Sep 1, 2021	clinicaltrials
NCT05006664	Brentuximab Vedotin in Combination With CHEP in Patient With PTCL	unknown	Phase 2	33

Molecule

Record

Kind: Adc
Mechanism: Tubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agent
Targets: 16 genes
UNII: 7XL5ISS668
Aliases: ADCETRIS, Brentuximab Vedotin, Brentuximab vedotina, Brentuximab vedotin brentuximab, Brentuximab vedotine, CAC-10, CAC10, Cac10-1006(4), CAC10-VCMMAE, Cac10-vcmmae(4), Monoclonal antibody sgn-30, Sgn 30, SGN-35

Data updated 2 days agoSource updated unknown

Identifiers

Codes (4)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FX05	BRENTUXIMAB VEDOTIN
DIN (Health Canada)	02401347	ADCETRIS
DPD drug code